Notably, vandetanib a multi-target protein kinase inhibitor approved for thyroid cancer and currently being tested in clinical trial for AML patients (clinical trial ID: NCT02638428), was prescribed based on the mutations of both ERBB4 and FLT4 genes which were already detected in the primary tumour. Here, FLT4 is linked to thyroid gland carcinoma.